

## The effect of Nifedipine on the expression of type I collagen in gingival fibroblasts ☆

Bei Li<sup>a</sup>, Weibin Sun<sup>b,\*</sup>, Yong Ji<sup>c</sup>

<sup>a</sup>Department of Periodontology, Dental Research Institute, Stomatological college, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China;

<sup>b</sup>Department of Periodontology, Stomatology hospital, Nanjing University, Nanjing 210029, Jiangsu Province, China;

<sup>c</sup>Department of Pathophysiology, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

Received 18 December 2007

### Abstract

**Objective:** To investigate the effect of nifedipine (calcium channel blocker) on the expression of collagen in gingival fibroblasts *in vitro*. **Methods:** Primarily gingival fibroblasts were cultured and incubated with various concentrations of nifedipine (108  $\mu$ g/L, 360  $\mu$ g/L and 1200  $\mu$ g/L) for 5 days. Gingival fibroblasts were primarily cultured derived from nifedipine responders and non-responders in the presence of 360  $\mu$ g/L nifedipine. Enzyme-linked immunosorbent assay was used to evaluate the amount of type I collagen. Cell proliferation was measured by cell counting with evaluating MTT value. **Results:** The expressions of collagen and cell proliferation were significantly different among the high concentration groups and the others on the fifth day, especially higher in 360  $\mu$ g/L and 1200  $\mu$ g/L groups and also different among nifedipine responders and non-responders. **Conclusion:** The expression of collagen and cell proliferation may be concerned with the biological mechanism for gingival overgrowth.

**Key words:** fibroblast; gingival hyperplasia; type I collagen; nifedipine

### INTRODUCTION

Nifedipine, the dihydropyridines calcium-channel blocking agent, is used widely to treat symptoms of coronary heart disease (CHD) and hypertension. Gingival overgrowth may occur as a side-effect in patients receiving nifedipine medication. However, the molecular mechanism of drug-induced gingival overgrowth is not definitively known. Many studies showed that collagen (COL), one of the connective tissue extracellular matrix, (ECM) especially type I collagen (COL-1), accumulates in hyperplastic tissue induced by nifedipine. Under physiological conditions, for COL-1 (one of the major components in the gingival connective tissue) a dynamic

balance between its synthesis and degradation, is essential. The objective of this study is to investigate the effect of nifedipine on the expression of collagen in gingival fibroblasts, suggesting a biological mechanism for gingival overgrowth *in vitro*.

### MATERIALS AND METHODS

#### Cells culture

Human normal gingival fibroblasts were obtained during surgical removal of impacted wisdom teeth from a healthy volunteer. The specimens of nifedipine responders and non-responders were obtained from patients who had developed gingival overgrowth as a result of nifedipine medication and patients who did not develop gingival overgrowth following nifedipine medication. The gingiva was cultured by the tissue explants method.

#### Drugs

☆ This work was supported by the Natural Science Foundation of the Department of Education of Jiangsu (BK2006172)

\*Corresponding author.

E-mail address: [wbsun@njmu.edu.cn](mailto:wbsun@njmu.edu.cn)

To prepare the nifedipine(Nanjing NO.1 Pharmacy Co., Ltd) medium concentrations of 108  $\mu\text{g/L}$ , 360  $\mu\text{g/L}$  and 1200  $\mu\text{g/L}$ , containing 0.01% pure ethanol(vehicle, Sigma, USA) and ascorbic acid(50  $\mu\text{g/ml}$ , Sigma, USA) which is essential for collagen synthesis was used.

### Cell proliferation

Normal human gingival fibroblasts were cultured with nifedipine medium as follows: Group I :108  $\mu\text{g/L}$  of nifedipine; Group II :360  $\mu\text{g/L}$  of nifedipine; Group III : 1200  $\mu\text{g/L}$  of nifedipine; Group IV: only medium as control. Fibroblasts were harvested for cell counting after 1, 3 and 5 days. Four gingival fibroblast strains(GF-1, -2,-3,-4) from nifedipine responders and non-responders were cultured in DMEM, supplemented with 360  $\mu\text{g/L}$  nifedipine. We observed the effect of cell proliferation by evaluating MTT value after 1, 3 and 5 days.(GF-1,-2: nifedipine non-responders;GF-3,-4:nifedipine responders)

### Enzyme-linked immunosorbent assay(ELISA)

The production of type I collagen was assayed using a special ELISA. The supernatant of media was collected after 1, 3 and 5 days. The protein contents of COL-1 were measured by a human COL-1 ELISA kit (Zhangshan Goldenbridge Biotechnology Co., Ltd)

according to the manufacturer's instructions.

### Statistical analysis

The data was expressed as mean  $\pm$  SD and was analyzed by ANOVA with SPSS software. Significant differences were noted at a *P*-value of  $< 0.05$ .


## RESULTS

### Cell growth

Generally, the number of cells of every group increased from 1 to 5 days. ANOVA application demonstrated in 3 days between each group multiplies were not obvious different, but in the 5th day each group displayed significant difference(**Tab 1**, **Tab 2** and **Fig 1**). The results showed statistical difference between nifedipine responders and non-responders on days 1, 3 and 5(**Tab 3** and **Tab 4**).

### ELISA

**Fig 2** illustrated that the expression of COL-1 coincided with the results of cell proliferation. In the 1st and 3rd day between each group synthesis were not obvious different, but on the 5th day each group displayed significant difference. The results showed statistical difference between nifedipine responders and non-responders on 1, 3 and 5 days(**Fig 3**).



**Fig 1** Microphotographs of cultured gingival fibroblasts on 5th day( $\times 100$ )

**Tab 1** Cell proliferation in 4 groups

				( $\times 10^4$ , $\bar{x} \pm s$ )		
group I	group II	group III	group IV	<i>F</i>	<i>P</i>	Value
0 th day	3.00 $\pm$ 0.00	3.00 $\pm$ 0.00	3.00 $\pm$ 0.00	3.00 $\pm$ 0.00		
1 st day	2.88 $\pm$ 0.18	5.00 $\pm$ 2.83	6.50 $\pm$ 2.12	2.70 $\pm$ 0.141	2.107	0.24
3 rd day	6.25 $\pm$ 2.12	11.50 $\pm$ 1.41	11.50 $\pm$ 2.12	5.55 $\pm$ 3.32	3.820	0.11
5 th day	9.00 $\pm$ 3.18	18.00 $\pm$ 1.41	30.50 $\pm$ 4.95	8.00 $\pm$ 4.24	15.950	0.01

**Tab 2** Post HOC Comparisons on 4 groups

	group	I	II	III
5 th day	II	0.029		
	III	0.004	0.065	
	IV	0.004	0.049	0.799

## DISCUSSION

Nifedipine and dihydropyridines(the calcium blocking agent) is widely used in the treatment of ischemic

cardiovascular disease, such as angina pectoris and hypertension<sup>[1]</sup>. Since the first report<sup>[2]</sup> of nifedipine-induced gingival overgrowth, many clinical cases<sup>[3-4]</sup> indicated that gingival overgrowth may occur as a side-effect in patients receiving nifedipine medication. The prevalence rate of nifedipine-induced gingival overgrowth is 20% to 83%<sup>[5]</sup>.



The mechanism of drug-induced fibrosis is not fully understood. In general, it is possible that it is related

**Tab 3** Cell proliferation in 4 groups of nifedipine responders and non-responders (OD<sub>492</sub>,  $\bar{x} \pm s$ )

GF-1	GF-2	GF-3	GF-4	F	P	valve
1 st day	0.0087 $\pm$ 0.0020	0.0073 $\pm$ 0.0011	0.0240 $\pm$ 0.0015	0.0142 $\pm$ 0.0022	18.042	0.000
3 rd day	0.0178 $\pm$ 0.0010	0.0120 $\pm$ 0.0011	0.0458 $\pm$ 0.0030	0.0275 $\pm$ 0.0025	48.942	0.000
5 th day	0.0313 $\pm$ 0.0024	0.0217 $\pm$ 0.0028	0.1318 $\pm$ 0.0082	0.0963 $\pm$ 0.0082	75.428	0.000

**Tab 4** Post HOC comparisons on 4 groups

	group	GF-1	GF-2	GF-3
1 st day	GF-2	0.603		
	GF-3	0.000	0.000	
	GF-4	0.041	0.013	0.001
3 rd day	GF-2	0.078		
	GF-3	0.000	0.000	
	GF-4	0.007	0.000	0.000
5 th day	GF-2	0.274		
	GF-3	0.000	0.000	
	GF-4	0.000	0.000	0.001

**Fig 2** Effect of nifedipine on the expression of type I collagen of normal gingival fibroblasts**Fig 3** Effect of nifedipine on the expression of type I collagen of nifedipine responders and non-responders

with cell proliferation of gingival fibroblasts promoted by nifedipine. Fujii<sup>[6-9]</sup> et al. demonstrated that fibroblasts from patients reacting to nifedipine gave trends toward better cell proliferation rate, DNA synthesis as compared with those without nifedipine. However this data didn't agree with the results of Salo<sup>[10]</sup>, who showed that 100  $\mu\text{g/L}$  and 200  $\mu\text{g/L}$  nifedipine had no effect on the cell proliferation in normal human gingival fibroblasts. Ellis<sup>[11]</sup> et al reported that the concentration of nifedipine in gingival crevicular fluid in patients receiving nifedipine was 0.92~9.30  $\mu\text{g/ml}$ , 15~90 fold higher than that in plasma. In this study, we chose various concentrations of nifedipine according to concentration

gradient: 108  $\mu\text{g/L}$ , 360  $\mu\text{g/L}$  and 1200  $\mu\text{g/L}$ . Our results showed that cell proliferation is dependent on time and dose, it is that long time and high concentration promoted cell growth, which agree with the results of our early studies.

Many studies do not support that nifedipine can result in cell proliferation, but suggest that collagen accumulation may work. For COL-1, one of the components in the gingival connective tissue and extracellular matrix, a dynamic balance between its synthesis and degradation is essential. Spolidorio<sup>[12]</sup> et al demonstrated a disturbance tissue homeostasis led to an accumulation of extracellular matrix in gingival overgrowth, in particular COL-1. Nakao<sup>[13]</sup> et al reported that in hyperplastic gingiva compared to normal tissues, the level of expression of collagen increased. Kataoka<sup>[14]</sup> et al reported that the contents of collagen in rats gingival connective tissues (which were fed by nifedipine) lead to gingival overgrowth compared with the normal rats, and was shown as obviously increased by the results of immunohistochemistry. All those suggested that extracellular matrix degradation depressed and collagen deposited by nifedipine may be the mechanism of gingival overgrowth. We showed that the results were the same as cell proliferation, depending on time and dose. Our data suggested that collagen secreted by fibroblasts was raised by nifedipine, which proved collagen stacked in histology.

In our study, the results of cell proliferation and ELISA showed that the high concentration of nifedipine could stimulate the expression of type I collagen. But for the molecular mechanism, such as the gene regulation of gingival fibroblast extracellular matrix by nifedipine is still to be investigated.

## References

- [1] Johnson RB. Synergistic enhancement of collagenous protein synthesis by human gingival fibroblasts exposed to nifedipine and TNF-alpha in vitro. *J Oral Pathol Med* 2003;32:408-13.
- [2] Ramon Y, Behar S, Kishon Y, Engelberg IS. Gingival hyperplasia caused by nifedipine-a preliminary report. *Int J Cardiol* 1984;5:195-206.
- [3] Ikawa K, Ikawa M, Shimauchi H, Iwakura M, Sakamoto S. Treatment of gingival overgrowth induced by nifedipine administration. *J Periodontol* 2002;73:115-22.
- [4] Naidoo LC, Stephen LX. Nifedipine-induced gingival hyperplasia: non-surgical management of a patient. *Spec Care Dentist* 1999;19:29-34.
- [5] Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason

- JM. Prevalence of gingival overgrowth induced by calcium channel blockers. *J Periodontol* 1999;70:63-7.
- [6] Fujii A, Matsumoto H, Nakao S, Teshigawara H, Akimoto Y. Effect of calcium-channel blockers on cell proliferation, DNA synthesis and collagen of cultured gingival fibroblasts derived from human nifedipine responders and nonresponders. *Arch Oral Biol* 1994;39: 99-104.
- [7] Takeuchi R, Matsumoto H, Okada H, Hori M, Gunji A, Hakozaiki K, et al. Difference of cell growth and cell cycle regulators induced by basic fibroblast growth factor between nifedipine responders and non-responders. *J Pharmacol* 2007;103:168-74.
- [8] Sato N, Matsumoto H, Akimoto Y, Fujii A. The effect of IL-1  $\alpha$  and nifedipine of cell proliferation and DNA synthesis in cultured human gingival fibroblasts. *J Oral Sci* 2005;47:105-10.
- [9] Matsumoto H, Noji I, Akimoto Y, and Fujii A. Comparative study of calcium channel blockers on cell proliferation, DNA and collagen syntheses, EGF receptor of cultured gingival fibroblasts derived from human nifedipine, nicardipine, nisoldipine responders. *J Oral Sci*, 2001;43:267-74.
- [10] Salo T, Oikarinen KS, Oikarinen AI. Effect of phenytoin and nifedipine on collagen gene expression in human gingival fibroblasts. *J Oral Path Med* 1990;19:404-7.
- [11] Ellis JS, Seymour RA, Monkman S, Idle JR. Disposition of nifedipine in plasma and gingival crevicular fluid in relation to drug induced gingival overgrowth. *J Periodont Res* 1993;28:373-8.
- [12] Spolidorio LC, Spolidorio DM, Neves KA, Gonzaga HF, Almeida OP. Morphological evaluation of combined effects of cyclosporine and nifedipine on gingival overgrowth in rats. *J Periodontal Res* 2002;37:192-5.
- [13] Nakao K, Yoneda K, Osaki T. Enhanced cytokine production and collagen synthesis of gingival fibroblasts from patients with denture fibromatosis. *J Dent Res* 1995;74:1072-8.
- [14] Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Azuma H, Sawa T, et al. Nifedipine induces gingival overgrowth in rats through a reduction in collagen phagocytosis by gingival fibroblasts. *J Periodontol* 2001;72:1078-83.

## Current approaches of genome-wide association studies

Jianfeng Xu

Wake Forest University School of Medicine  
Winston-Salem, North Carolina, U.S.A

With rapid advances in high-throughput genotyping technology and the great increase in information available on SNPs throughout the genome, genome-wide association(GWA) studies have now become feasible. By testing associations of diseases or traits with a large number of SNPs that capture most of the genetic information across the genome, GWA approaches can identify variants that directly or indirectly confer risk. The systematic and objective nature of GWA increases the likelihood of identifying risk variants and may reveal novel mechanisms. The power of this approach has been empirically demonstrated by the recent success of GWA studies in many diseases, including cancers.

Approaches to design, implement, and analyze GWA studies will evolve rapidly. I will first discuss study design issues in terms of study populations, sample sizes, SNP platforms, and multiple stages of confirmation. I will then discuss quality control issues in genotyping and data analyses. I will describe several approaches to analyze GWA data, including genetic models, imputation, and gene-environment and gene-gene interactions. Finally, I will discuss the utility of results from GWA studies.